Abstract:Objective:To observe the adverse reactions caused by different doses of N-acetylcysteine(NAC) in treatment of patients with severe liver diseases for an approach to the drug safe use.Methods:Between February 2006 and January 2008,173 patients with various patterns of severe liver diseases in our hospital were enrolled in the study.One hundred and seventy-three patients were divided into 3 groups:the high-dose group(25 cases),the low-dose group(66 cases),and the dose-escalation group(82 cases).The high-dose group comprised 16 men and 9 women with average age(42.3±3.6) years.The low-dose group comprised 42 men and 24 women with average age(41.6±4.8) years.The dose-escalation group comprised 51 men and 31 women with average age(45.2±5.2) years.The drug administration was as follows:the patients in the high-dose group were administered an IV infusion of NAC 8 g dissolved in 10% glucose 250 ml once daily;the patients in the low-dose group were administered NAC 4 g dissolved in 10% glucose 250 ml once daily,while oral famotidine 20 mg twice daily and slowly IV push of 10% calcium gluconate 10 ml mixed with 50% glucose 20 ml were given.The patients in the dose-escalation group received an initial dose of IV NAC 4 g/d,and if no adverse reaction occurred,the dose of NAC was increased to 8 g/d on day 4.The administration and other medications were the same as those in the low-dose group.All patients were observed at least two weeks.Results:In the high-dose group,adverse reactions occurred in 16 cases(64%) of 25 patients including 9 cases(36%) of skin disorders,2 cases(8%) of chest distress and dizziness,3 cases(12%) of gastrointestinal disorders,one case(4%) of anaphylactic shock,and one case(4%) of lower limbs dyskinesia.The Model for End-Stage Liver Disease(MELD) scores to the patients experiencing adverse reactions and the patients no experiencing adverse reactions in the high-dose group were 11.26±5.47 and 18.38±5.71,respectively.The difference was statistically significant(P<0.05).It indicated that the condition of patients experiencing adverse reactions was mild.In the low-dose group,adverse reactions occurred in 2 cases(3.03%) of 66 patients including 1 case of rash,and 1 case of upper abdominal discomfort.The incidence of adverse reactions in the low-dose group was lower than that in the high-dose group.The difference was statistically significant(P<0.001).The MELD scores in the patients experiencing rash and the patients experiencing upper abdominal discomfort were 11.38 and 10.29,respectively.In the dose-escalation group,4 patients(4.88%) developed adverse reactions within 3 days of treatment;seven(8.97%) of other 78 patients developed adverse reactions in more than 4 days of treatment,and the incidence was higher than the low-dose group and lower than the high-dose group(all P<0.001).Of the 78 patients,31 patients'MELD score was >15,and one case of gastrointestinal disorders and one case of skin rash occurred;47 patients'MELD score was <15,and 3 case of gastrointestinal disorder,one case of scalp swelling and one case of skin rash occurred.The difference between both of them was statistically significant(P< 0.001).The patients'adverse reactions disappeared after discontinuation of the drug and symptomatic treatment.Conclusion:Low-dose or dose-escalation NAC combined with oral famotidine and IV calcium gluconate 10% is a safe regimen in treatment of severe liver diseases,but relatively mild cases of severe liver diseases should be closely monitored during treatment in order to avoid or decrease adverse reaction occurring.

N-acetylcysteine in children with dengue-associated liver failure: a case report

Use of intravenous N-acetylcysteine in acute severe hepatitis due to severe dengue infection: a case series

Role of Plasma Exchange and Combining Therapies in Dengue-Associated Acute Liver Failure: A Systematic Review of Individual Cases

A rare case of acute liver failure with intrahepatic cholestasis due to dengue hemorrhagic fever: CytoSorb® and plasma exchange aided in the recovery: case report

N-acetylcysteine for non-acetaminophen induced acute liver failure: A review

Therapeutic plasma exchange in expanded dengue patients having acute liver failure: A case series

N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review

Acute Liver Failure with Intracerebral Hemorrhage in Dengue Fever: A Rare Clinical Presentation

N-Acetylcysteine for Preventing Acetaminophen-Induced Liver Injury: A Comprehensive Review

The Use and Potential Benefits of N-Acetylcysteine in Non-Acetaminophen Acute Liver Failure: An Etiology-Based Review

Association of Liver Function Tests With the Severity and Outcome of Dengue Fever in Children

Liver involvement in dengue: A systematic review

Acute acalculous cholecystitis in a pediatric dengue hemorrhagic fever patient: A case report, lesson learned from limited resource setting

A Case Report of a Severe, Unusually Delayed Anaphylactoid Reaction to Intravenous N-Acetylcysteine During Treatment of Acute Acetaminophen Toxicity in an Adolescent

Acute liver failure in children

Dengue hepatitis with acute liver failure: Clinical, biochemical, histopathological characteristics and predictors of outcome

Efficacy of Non-Bioartificial Liver in the Treatment of Children with Acute Liver Failure

Study on clinical safety of different doses of N-acetylcysteine in treatment of patients with severe liver diseases

Child Neurology: Acute Necrotizing Encephalopathy of Childhood Associated With Dengue: Good Neurologic Outcome Despite a Fulminant Presentation

Stem Cell Therapy in Dengue Virus-Infected BALB/C Mice Improves Hepatic Injury

Effects of Plasma Exchange Combined with Continuous Renal Replacement Therapy on Acute Fatty Liver of Pregnancy.